Ozon Pharmaceutics Profit Up 90% in First Half
The net profit of PJSC "Ozon Pharmacy" for the first half of the year, according to IFRS, amounted to 3.2 billion rubles, which is 90% higher than in the previous year.
Consensus
- Ozon Pharmaceutics' net profit for the first half of the year increased by 90% year on year.
- Net profit for the first half of the year amounted to 3.2 billion rubles.
- Revenue for the first half of the year rose by 12% to 14.8 million rubles.
- Adjusted EBITDA increased by 33% year on year to 5.8 billion rubles.
- The company's profitability reached 39%.
- The company confirmed its forecast for revenue growth in 2026 of 15–25% year on year.
- Capital expenditures increased by 17% year on year to 2.3 billion rubles.
- Free cash flow amounted to 4.5 billion rubles.
- The company's net working capital decreased by 17% to 17.9 billion rubles.
Points of divergence
- The company reported a 30% increase in net profit in the first quarter of 2026 compared to the same period in 2025, reaching 1.3 billion rubles. — vedomosti
- Retail sales in rubles grew by 14% year on year, while the market grew by 12%. — vedomosti
- Retail sales in units decreased by 3% year on year, with a 2% decline in packaging volume and a 0.4% increase in unit volume. — vedomosti
- The company's net profit margin increased by 9 percentage points to 22%. — komersant
- The debt-to-EBITDA ratio decreased to 0.4x due to planned debt repayment and use of factoring. — komersant
- Ozon Pharmaceutics is a leader in drug production in Russia, specializing in traditional low-molecular pharmaceuticals, high-toxicity oncology drugs, and complex biotech drugs. — komersant
Coverage (2 sources)
- Net profit of Ozon Pharmacy for the first half of the year according to IFRS increased by 90% — Ведомости
- Net profit of Ozon Pharmacy under IFRS doubled in the first half of the year — Коммерсантъ